battenkillbbsiiireel| Jianfeng Group (600668.SH): Imatinib mesylate received approval notice for chemical API marketing application
Gelonghui May 13 丨 Jianfeng Group (600668)(600668battenkillbbsiiireel.SH) Announcementbattenkillbbsiiireel, the wholly-owned subsidiary Zhejiang Jianfeng Pharmaceutical Co., Ltd. received a notice from the State Food and Drug Administration on the chemical raw material imatinib mesylatebattenkillbbsiiireel"Notice of Approval for Marketing Application for Chemical Raw Materials". Imatinib mesylate is the mesylate salt of imatinib, a tyrosine kinase inhibitor with antitumor activity.
Tags：
Recommendations
- crashteamracingnitrofueledyuzu|Sudan dam collapse leaves at least 60 dead, hundreds missing
- onlinecasinowithfreesignupbonusrealmoney|Jordan launches initiative to support amputees in Gaza
- reelpennbattle35000|Feature: Bringing centuries-old tea experience to modern Taipei
- othercryptogames|Across China: Guarding greenery on northeast China's Changbai Mountain
- playslotsforrealmoneynodeposit|Villagers dry agricultural products in county of Yichun, E China
- casinoswithfreeplayfornewmembers|China's Gansu launches support policies for signature beef noodles industry
- firstpersonroulette|Aerial view of Harbin, China's "Ice City"
- pennpursuitthree|Across China: Wetland tourism heats up in China's "ice city"
- crashland|Explainer: China pilots housing pension system to enhance people's living quality
- xplaybetcasinonodepositbonus|Senior CPC official meets Cambodian deputy PM